QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-acceptance-of-rocket-pharmaceuticals-lead-gene-therapy-application-reestablishes-momentum-for-stock

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by Mar...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 the-fda-has-accepted-the-resubmission-of-rocket-pharmaceuticals-marketing-application-for-kresladi-marnetegragene-autotemcel-marne-cel-an-investigational-gene-therapy-for-severe-leukocyte-adhesion-deficiency-i-pdufa-date-is-march-28-2026

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KR...

 leerink-partners-maintains-market-perform-on-rocket-pharmaceuticals-lowers-price-target-to-7

Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the p...

 fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

 rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-martin-wilson-appointed-interim-cfo-effective-september-8

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangemen...

 the-european-medicines-agency-just-disclosed-that-rocket-pharmaceuticals-has-withdrawn-its-application-for-marketing-authorization-of-fanskya-the-ema-concluded-that-the-benefit-of-mozafancogene-autotemcel-did-not-outweigh-its-risks---ema

https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-moz...

 b-of-a-securities-upgrades-rocket-pharmaceuticals-to-buy-raises-price-target-to-10

B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the pr...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy

Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and update...

 the-fda-lifts-clinical-hold-on-rocket-pharmaceuticals-pivotal-phase-2-trial-of-rp-a501-for-danon-disease

In its correspondence, the FDA confirmed that Rocket satisfactorily addressed issues outlined in the clinical hold. The FDA aut...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-lowers-price-target-to-11

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price targe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION